Research Article
UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells
Figure 4
Knockdown of UBE2C sensitizes DDP-resistant NSCLC cells to cisplatin via decreasing the expression of ZEB1/2. A549/DDP or H1299/DDP cells were transfected with UBE2C or siUBE2C. ZEB1 or ZEB2 were used for upregulated the protein level of UBE2C target genes and then treated with DDP 6 μg/ml for 48 h, respectively. (a, b) The mRNA and protein expression levels of UBE2C and ZEB1 (a) or UBE2C and ZEB2 (b) were analyzed by RT-PCR and immunoblotting assay. (c–f) The cellular growth was analyzed by CCK8 assay with or without treatment of DDP at 6 μg/ml for 48 h in A549/DDP (c, d) or H1299/DDP (e, f) cells. (g) The protein of Ki67 was analyzed by immunofluorescent staining. (h) The protein of active caspase-3 was analyzed by Western blot. (i) The protein of Annexin V was analyzed by immunofluorescent staining. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. p<0.05; p<0.01 versus control group.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |